PayerTalkCE® Presents: Emerging HER2-targeting Therapies for the Management of GI Cancers

Learn About:

  1. Innovations in HER2-targeting therapies and their role in the treatment of select gastrointestinal cancers
  2. Integration of new treatments into health care systems, insurance coverage, reimbursement challenges, and the overall impact on health care policy

Expert Faculty Presenters:

Shubham Pant, MD
Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Click here for biography

Jeffrey D. Dunn, PharmD, MBA
President and CEO
Cooperative Benefits Group (CBG)
Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
In this episode of PayerTalkCE®, we will delve into the innovations around HER2-targeting therapies and their role in the treatment of select gastrointestinal cancers. Topics will include the latest evidence and the integration of new treatments into health care systems, insurance coverage, reimbursement challenges, and the overall impact on health care policy.

Educational Objectives
After completing this activity, the participant should be better able to:

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
Partners designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Partners designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: 4008073-9999-25-131-L01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Disclosure of Conflicts of Interest
Partners for Advancing Clinical Education (Partners) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to Partners policy. Partners is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Name of Working Group Members/Planners

Reported Financial Relationship
Shubham Pant, MD Consultant/Advisor/Speaker: Ipsen, Novartis, Daiichi Sankyo, Janssen, AskGene Pharma, BPGBio, Jazz Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Alligator Bioscience, Theriva Biosciences, USWorldmeds, Nihon Medi-Physics Co, Ltd, Revolution Medicine, Arcus, BMS, Merck, Pfizer

Research funding (funding to institution): Mirati Therapeutics, Lilly, Novartis, BMS, Boehringer Ingelheim, Janssen, Arcus, Elicio, Ipsen, Zymeworks, Pfizer, ImmunoMET, Immuneering, Amal Therapeutics, Jazz Therapeutics, Revolution medicine

Stock: Telperian
Jeffrey D. Dunn, PharmD, MBA Nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.